Literature DB >> 28699784

Cancer drugs and QT prolongation: weighing risk against benefit.

Pierantonio Menna1, Emanuela Salvatorelli1, Giorgio Minotti1.   

Abstract

Entities:  

Keywords:  Cancer drugs; QT prolongation; comorbidities; risk:benefit ratio

Mesh：

Substances：

Year:  2017        PMID： 28699784     DOI： 10.1080/14740338.2017.1354987

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN： 1474-0338            Impact factor:   4.250


× No keyword cloud information.
  3 in total

Review 1.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

2.  QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

Authors:  Tri Le; Hui Yang; Sawsan Rashdan; Mark S Link; Vlad G Zaha; Carlos Alvarez; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-11-25       Impact factor: 4.785

3.  Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study.

Authors:  Joanna C Masters; Naveed Shaik; Laure Mendes da Costa; Brian Hee; Robert R LaBadie
Journal:  Clin Pharmacol Drug Dev       Date:  2020-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.